GSK Pharma Q4 PAT seen down 51% to Rs 101 cr

ALSO READ News and Notices about GlaxoSmithKline See interviews with GlaxoSmithKline Management See what other Experts & Brokerages are saying about GlaxoSmithKline See previous Results of GlaxoSmithKline GlaxoSmithKline BSE | NSE 10/02/12 Are Mutual Funds betting on GlaxoSmithKline?

GlaxoSmithKline Pharmaceuticals is to announce its fourth quarter results. According to CNBC-TV18 estiamtes, the company's Q4 revenue are seen up 10.2% to Rs 413.2 crore versus Rs 374.87 crore.

Its OPM is seen flat at 29.7%.

The company's PAT is seen down 51.26% at Rs 101.59 crore versus Rs 208.47 crore.

• Topline growth led by double-digit growth in Priority Products (60-70% of sales)
• DPCO products (~26% of sales) are likely to record single-digit revenue growth
• Margins stagnant due to higher promotional expenditure for new launches and higher staff costs
• PAT is expected to grow mainly due to decline in EBITDA Margins
• Expected to record ~10-12% growth for the next two years
• Parent is fully committed to the listed entity
• Evident from the fact that it is proposing to launch most of the patented products through the listed entity